Ketamine-Based Mental Health Services: Questions for Program Evaluation

A ketamine-based mental health service should be evaluated by the exact medicine, route of administration, diagnosis, monitoring arrangements, and follow-up plan. “Ketamine therapy” can describe substantially different treatments. An intravenous infusion, an authorized esketamine nasal spray, and a compounded take-home product should not be treated as equivalent offers.

For someone considering care abroad, the most important question is whether the full course and continuing care can be delivered safely and lawfully. A program promising rapid improvement still needs to explain who is suitable, what happens if treatment does not help, and how care continues after the patient returns home.

Identify exactly what the service is offering

Ask for the generic medicine name, formulation, route, treatment setting, and clinical indication. Also ask whether psychological therapy is included, who provides it, and how it relates to medical treatment. A broad label can conceal different prescribing practices and different evidence.

Ask the clinician to explain these distinctions without using the reputation of one product to justify another. The FDA’s warning about compounded ketamine states that ketamine is not FDA-approved for psychiatric disorders and that compounded products have not undergone FDA approval for those uses.

Separate authorization, evidence, and payment coverage

These are three different questions. Authorization concerns a medicine’s approved use in a jurisdiction. Clinical evidence concerns benefits and harms in particular patients under a particular protocol. Payment coverage concerns whether an insurer or public system will pay for that treatment.

The US Spravato prescribing information includes treatment-resistant depression in adults, either alone or with an oral antidepressant. It also has a separate indication involving depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior, alongside an oral antidepressant. These indications do not establish approval for every mental health condition.

In England, NICE’s appraisal does not recommend esketamine nasal spray with an SSRI or SNRI for the specified treatment-resistant depression indication within its marketing authorization. A negative funding recommendation is not the same statement as a medicine having no license or no clinical evidence.

Ask the service to identify the rules that apply where treatment occurs. A US label cannot be assumed to govern prescribing in Europe, and private availability does not establish reimbursement.

Assessment should come before purchasing a course

A psychiatric assessment should clarify the diagnosis, previous treatment, current medication, physical health, substance use, and the patient’s ability to participate in follow-up. Ask how the clinician distinguishes persistent unipolar depression from bipolar symptoms or other conditions that may change the recommendation.

As one example of a defined medical pathway, Oxford Health’s ketamine service describes reviewing referral information and assessing suitability before treatment. This illustrates the role of clinical screening; it is not a statement that every international patient is eligible for that service.

Be prepared to discuss previous episodes of mania, psychosis, cardiovascular problems, pregnancy, urinary symptoms, and difficulties with ketamine or other substances. The significance of each needs individual medical evaluation. An online questionnaire or an admissions conversation alone should not be presented as a comprehensive psychiatric and physical-health assessment.

Ask how risks are monitored during and after sessions

Ketamine-based treatment can affect perception, alertness, blood pressure, and judgment. The exact risks depend on the medicine, route, patient, and other substances being used. The service should explain who monitors the patient and what equipment, staff, and escalation arrangements are available.

For US Spravato treatment, the label requires supervised administration and at least two hours of monitoring, with assessment of readiness to leave. It also identifies risks including sedation, dissociation, respiratory depression, abuse, and misuse. Those requirements should not be generalized into a universal monitoring schedule for every ketamine formulation.

Oxford Health’s risk information discusses unpleasant experiences and uncertainties about longer-term use, including dependence, tolerance, and bladder or cognitive concerns. Ask how the service checks for emerging problems over time rather than treating each session as an isolated event.

Tell the team about alcohol, sedating medicines, stimulants, and nonprescribed substances. Do not stop regular medication or alter doses on your own to prepare for treatment. The prescriber should provide clear instructions and coordinate with the existing clinician.

Rapid improvement does not establish durable recovery

A short-term change in mood can be meaningful, but it does not answer how long improvement lasts or what ongoing treatment is needed. Ask when benefit is measured, how it is defined, and what happens after an initial response.

Oxford Health’s service information emphasizes that ketamine treatment is not necessarily a one-off intervention and that repeated travel can affect practicality. A clinic’s experience is not a universal forecast, but it highlights a question every international program should answer: what is the realistic continuing-care commitment?

Ask for evidence matching the proposed formulation and diagnosis. A depression study should not be used as proof of effectiveness for trauma, anxiety, addiction, or general wellness. If the service cites a research trial, check whether its own protocol and patients resemble those in the study. Our outcome-claim guide explains why response percentages need denominators, follow-up dates, and information about people who stopped treatment.

Examine the therapy component separately

“Ketamine-assisted therapy” should describe more than having a supportive person nearby. Ask what happens before, during, and after the medical session; which psychological approach is used; and what qualifications the therapist holds. Clarify whether therapy is an optional additional service or an essential part of the proposed protocol.

Consent and boundaries should be agreed while the patient is fully able to consider them. Ask who may enter the room, whether sessions are recorded, whether touch is proposed, and how a patient can decline a component or make a complaint. Privacy and patient choice remain relevant when an intervention changes awareness or perception.

Preparation can help a person understand the experience, while subsequent therapy may address the person’s goals and difficulties. Neither term should be used to promise that a powerful subjective experience necessarily produces lasting clinical improvement. Request the evidence for the combined treatment rather than accepting a theory as proof.

Keep emergency psychiatric care distinct

The US Spravato label explicitly says that effectiveness in preventing suicide or reducing suicidal thoughts or behavior has not been demonstrated, and treatment does not remove the need for hospitalization when clinically warranted. A person at immediate risk needs urgent assessment through local emergency or crisis services.

A retreat should not use the possibility of a rapid antidepressant effect to imply that it can safely receive anyone in crisis. Ask whether the proposed setting has the psychiatric and medical capacity the person needs before considering travel. Our assessment before treatment abroad guide explains how to establish the appropriate level of care.

Plan transport, observation, and the next day

Ask for written instructions about getting to and from treatment, accompaniment, driving, work, and other activities afterward. A taxi booking may not satisfy a service’s requirement for an escort. Clarify who checks that the patient is ready to leave and who remains available if symptoms arise after returning to accommodation.

Oxford Health’s information for carers describes the role of an escort in its service. Each provider should explain its own arrangements. If sessions are delivered at an outside clinic, the residential program and medical team should agree on responsibility for the journey and subsequent observation.

Do not plan a flight immediately after a session based only on an admissions team’s calendar. The treating clinician should advise on the timing and any clinical or practical concerns. International travel also requires checking the rules for any medicines supplied for use outside the clinic.

Compare the full course and the exit plan

Request separate costs for assessment, medication, administration, observation, therapy, investigations, transport, and follow-up. Ask how charges change if treatment is stopped because it is unsuitable, poorly tolerated, or ineffective. A prepaid package should not create pressure to continue an intervention without benefit.

Before starting abroad, identify the clinician who will review the patient at home. Confirm whether further treatment is available locally, whether that clinician accepts the proposed handover, and what happens if the formulation or protocol differs. Do not assume that medication can simply be posted internationally or that a foreign prescription can be filled locally.

Our medication coordination guide and aftercare planning guide address these transitions. If no workable continuation plan exists, discuss whether a local specialist service or a different treatment would offer a more coherent course of care.

A decision worth documenting

After assessment, ask the clinician to summarize why this treatment is being considered, the alternatives, the main uncertainties, and the conditions for reviewing or stopping it. Keep the patient’s goals visible alongside symptom measures: being able to function, reconnect, and sustain ordinary life matters beyond the experience of a treatment session.

A well-explained program can distinguish what is established from what is still uncertain. That allows the patient and their existing clinical team to make a considered decision without treating an innovative treatment as a guaranteed solution.